Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report

Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status...

Full description

Bibliographic Details
Main Author: Sebastian Kraus
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:Current Problems in Cancer: Case Reports
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2666621923000157
_version_ 1827923284618903552
author Sebastian Kraus
author_facet Sebastian Kraus
author_sort Sebastian Kraus
collection DOAJ
description Targeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with MET exon 14 (METex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with METex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for >8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.
first_indexed 2024-03-13T04:54:32Z
format Article
id doaj.art-547129d2555345518af346f872b75f23
institution Directory Open Access Journal
issn 2666-6219
language English
last_indexed 2024-03-13T04:54:32Z
publishDate 2023-06-01
publisher Elsevier
record_format Article
series Current Problems in Cancer: Case Reports
spelling doaj.art-547129d2555345518af346f872b75f232023-06-18T05:03:31ZengElsevierCurrent Problems in Cancer: Case Reports2666-62192023-06-0110100230Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case reportSebastian Kraus0Stadtspital Zürich Triemli, Klinik für Medizinische Onkologie und Hämatologie, Zürich, SwitzerlandTargeted therapies are recommended for treatment of patients with non-small cell lung cancer (NSCLC) with actionable driver mutations, including those with poor performance status, who otherwise have limited treatment options. However, clinical trial evidence in patients with poor performance status is often sparse, especially for newer drug classes. Tepotinib, an oral, once-daily MET inhibitor, was recently approved for the treatment of advanced/metastatic NSCLC with MET exon 14 (METex14) skipping based on the durable clinical activity observed in the Phase II VISION trial. We report an excellent response to tepotinib in a patient with metastatic NSCLC with METex14 skipping, which was achieved despite a poor baseline Eastern Cooperative Oncology Group performance status (ECOG PS) of 3, substantial symptom burden, and prior intolerance to chemotherapy. The patient attained a rapid, near-complete radiographic response, evident from the first tumor assessment at 2 months, which was maintained for >8 months (ongoing at the time of writing) and correlated with the alleviation of all disease-related symptoms and improvement in ECOG PS to 0. Tepotinib was well tolerated despite the poor clinical condition and prior intolerance to chemotherapy. This case report provides real-world evidence for the clinical effectiveness of tepotinib and indicates that a dramatic response can be attained without clinically significant adverse events, even in a patient who would typically be ineligible for clinical trials due to poor ECOG PS.http://www.sciencedirect.com/science/article/pii/S2666621923000157ChemotherapyClinical effectivenessIntolerabilityMET inhibitorReal-world evidence
spellingShingle Sebastian Kraus
Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
Current Problems in Cancer: Case Reports
Chemotherapy
Clinical effectiveness
Intolerability
MET inhibitor
Real-world evidence
title Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
title_full Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
title_fullStr Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
title_full_unstemmed Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
title_short Dramatic response to tepotinib in a highly symptomatic patient with metastatic MET exon 14 skipping non-small cell lung cancer and poor performance status: A case report
title_sort dramatic response to tepotinib in a highly symptomatic patient with metastatic met exon 14 skipping non small cell lung cancer and poor performance status a case report
topic Chemotherapy
Clinical effectiveness
Intolerability
MET inhibitor
Real-world evidence
url http://www.sciencedirect.com/science/article/pii/S2666621923000157
work_keys_str_mv AT sebastiankraus dramaticresponsetotepotinibinahighlysymptomaticpatientwithmetastaticmetexon14skippingnonsmallcelllungcancerandpoorperformancestatusacasereport